TY - JOUR
T1 - Phase II evaluation of ifosfamide/mesna in metastatic prostate cancer
T2 - A Southwest Oncology Group Study
AU - Williamson, Stephen K.
AU - Wolf, Michael K.
AU - Eisenberger, Mario A.
AU - O'Rourke, Mark A.
AU - Brannon, William
AU - David Crawford, E.
PY - 1996
Y1 - 1996
N2 - The combination of ifosfamide and mesna was evaluated in a phase II trial in the treatment of metastatic prostate cancer. Two separate groups of patients were to be evaluated: patients with no prior hormonal therapy and hormonally refractory patients. Patients were treated with ifosfamide 1.5 g/M2, and mesna at 30% of the ifosfamide dose was administered immediately before and 4 and 8 h after ifosfamide treatment. Both drugs were given i.v. daily for 5 days every 21 days. Response was assessed every 6 weeks. Of 29 eligible and evaluable patients with hormonally refractory disease, there were two partial responders for a response rate of 7% (95% confidence interval, of 0.1-23%). Of nine eligible patients with no prior hormone treatment, there was one partial response, for a response rate of 11% (95% confidence interval 0.348%). Unfortunately, the target accrual goal for this arm of the study was never achieved. The most common toxicities were myelosuppression and neurologic toxicity. These drugs do not warrant further evaluation in this disease.
AB - The combination of ifosfamide and mesna was evaluated in a phase II trial in the treatment of metastatic prostate cancer. Two separate groups of patients were to be evaluated: patients with no prior hormonal therapy and hormonally refractory patients. Patients were treated with ifosfamide 1.5 g/M2, and mesna at 30% of the ifosfamide dose was administered immediately before and 4 and 8 h after ifosfamide treatment. Both drugs were given i.v. daily for 5 days every 21 days. Response was assessed every 6 weeks. Of 29 eligible and evaluable patients with hormonally refractory disease, there were two partial responders for a response rate of 7% (95% confidence interval, of 0.1-23%). Of nine eligible patients with no prior hormone treatment, there was one partial response, for a response rate of 11% (95% confidence interval 0.348%). Unfortunately, the target accrual goal for this arm of the study was never achieved. The most common toxicities were myelosuppression and neurologic toxicity. These drugs do not warrant further evaluation in this disease.
KW - Ifosfamide
KW - Phase II trial
KW - Prostate neoplasms
UR - http://www.scopus.com/inward/record.url?scp=0030003387&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030003387&partnerID=8YFLogxK
U2 - 10.1097/00000421-199608000-00009
DO - 10.1097/00000421-199608000-00009
M3 - Article
C2 - 8677906
AN - SCOPUS:0030003387
SN - 0277-3732
VL - 19
SP - 368
EP - 370
JO - American Journal of Clinical Oncology: Cancer Clinical Trials
JF - American Journal of Clinical Oncology: Cancer Clinical Trials
IS - 4
ER -